Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross ProceedsJuly 25, 2025 3:04 PM EDT | Source: Phio Pharmaceuticals Corp.King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outsta ...

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth CohortJuly 25, 2025 12:36 PM EDT | Source: Phio Pharmaceuticals Corp.Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary I ...

Core Insights - Phio Pharmaceuticals has entered into a comprehensive drug substance development services agreement with a U.S. manufacturer for its lead compound PH-762, which is a significant step in advancing its intratumoral program for treating cutaneous carcinomas [1][2] - The company is currently enrolling patients for the fifth and expected final cohort in its Phase 1b dose escalation study targeting cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma [1][2] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at eliminating cancer [1][2] - The lead clinical program, PH-762, is designed to silence the PD-1 gene, which is implicated in various forms of skin cancer, and represents a potential non-surgical treatment option [2]

Core Insights - Phio Pharmaceuticals reported financial results for Q1 2025, highlighting advancements in its clinical trials for the siRNA lead product candidate PH-762, which aims to enhance immune cell effectiveness against cancer [1][2] Clinical Progress - The ongoing Phase 1b trial for PH-762 is evaluating its safety and tolerability in patients with various stages of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [2] - As of now, 10 patients have been treated across the first three cohorts, with 4 patients achieving a pathologic complete response, indicating 100% tumor clearance [3][4] Financial Results - At March 31, 2025, the company had cash of approximately $13.3 million, a significant increase from $5.4 million at December 31, 2024 [11] - Net cash provided by financing activities for Q1 2025 was approximately $9.2 million, compared to a net cash usage of approximately $4,000 in Q1 2024 [12] - Research and development expenses decreased by 23% to $0.886 million in Q1 2025 from $1.148 million in Q1 2024, primarily due to reduced salary-related costs and consulting expenses [13] - General and administrative expenses also saw a decrease of 7%, from approximately $1.061 million in Q1 2024 to approximately $0.986 million in Q1 2025 [14] - The net loss for Q1 2025 was $1.8 million, down from $2.2 million in Q1 2024, attributed to reduced operating expenses [15] Capital Sourcing - In late 2024 and early 2025, Phio raised approximately $9.2 million through registered direct offerings and private placements, along with an additional $2.9 million from warrant exercises, providing sufficient capital to complete the treatment phase of the Phase 1b trial [8] Cost Rationalization - The company has transitioned to a new laboratory facility with a monthly rent of approximately $2,500, and has contracted for additional working space at a fee of $300 per month [9]

Core Insights - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biotechnology company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to combat cancer [1][4] - The company announced podium presentations for its lead INTASYL product candidates, PH-762 and PH-894, at the 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany [1] Product Candidates - PH-762 is an INTASYL siRNA compound targeting PD-1, currently undergoing evaluation in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, showing promising preclinical efficacy and favorable tolerability [2][4] - PH-894 selectively silences BRD4, enhancing NK cell activation and proliferation without off-target effects, representing a novel approach to improve adoptive cell therapy [3] Conference Presentations - Melissa Maxwell, Phio's Director of Research and Program Management, will present on PH-762 during the Plenary Session 3, focusing on its preclinical advances and ongoing clinical evaluation [2] - PH-894 will be discussed in Plenary Session 11, highlighting its potential to increase NK cell activity for adoptive cell therapy [3]